Jack Bendheim Sells 7,040 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $54.64, for a total transaction of $384,665.60. Following the transaction, the chief executive officer directly owned 117,000 shares of the company’s stock, valued at $6,392,880. The trade was a 5.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, April 14th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $59.08, for a total transaction of $415,923.20.
• On Thursday, March 19th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.52, for a total transaction of $369,740.80.
• On Wednesday, March 18th, Jack Bendheim sold 10,560 shares of Phibro Animal Health stock. The stock was sold at an average price of $52.68, for a total transaction of $556,300.80.
• On Tuesday, March 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.66, for a total transaction of $272,764.80.
• On Friday, March 13th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.91, for a total transaction of $258,244.80.
• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Tuesday, February 24th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.37, for a total transaction of $361,644.80.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.

Phibro Animal Health Trading Up 5.9%

Shares of Phibro Animal Health stock opened at $57.07 on Friday. The stock has a market capitalization of $2.31 billion, a P/E ratio of 25.36, a price-to-earnings-growth ratio of 0.83 and a beta of 0.69. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a 50-day simple moving average of $53.37 and a 200 day simple moving average of $45.08. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were given a dividend of $0.12 per share. The ex-dividend date was Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. Phibro Animal Health’s dividend payout ratio (DPR) is 21.33%.

Key Headlines Impacting Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Recent quarterly results and FY‑2026 guidance support the rally — Phibro beat EPS and revenue expectations and set FY‑2026 EPS guidance of roughly 2.93–3.10, helping justify the higher share price. MarketBeat PAHC coverage
• Positive Sentiment: Upgrades and positive analyst notes (e.g., Zacks upgrade to Strong Buy and reaffirmations from boutique shops) have increased investor interest and buying pressure. Analyst coverage summary
• Neutral Sentiment: Citigroup initiated coverage with a “neutral”/hold rating and a $62 price target (roughly single‑digit upside vs. current levels). That provides formal coverage but not a buy endorsement. Citigroup initiation
• Neutral Sentiment: Media discussion about whether it’s “too late” after a ~234.5% rally is drawing attention — this can attract momentum traders but also encourages re‑rating/valuation debate among longer‑term investors. Yahoo Finance article
• Negative Sentiment: CEO Jack Bendheim has sold multiple blocks of shares recently (most recently 7,040 shares at ~$54.64 on Apr 16). While the trades were executed under a pre‑arranged Rule 10b5‑1 plan (which limits informational inference), repeated insider sales can create short‑term caution among investors. InsiderTrades report

Analyst Ratings Changes

PAHC has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research report on Friday, February 6th. Citigroup began coverage on shares of Phibro Animal Health in a research report on Wednesday. They issued a “neutral” rating and a $62.00 price objective for the company. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Phibro Animal Health has a consensus rating of “Hold” and a consensus price target of $42.40.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. Millennium Management LLC increased its position in Phibro Animal Health by 4,227.1% in the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares in the last quarter. Capricorn Fund Managers Ltd acquired a new stake in Phibro Animal Health in the 3rd quarter valued at about $10,233,000. JPMorgan Chase & Co. increased its position in Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after acquiring an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Finally, Advisors Preferred LLC acquired a new stake in Phibro Animal Health in the 3rd quarter valued at about $3,953,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.